RT Journal Article
SR Electronic
T1 Longitudinal viscosity of blood plasma for rapid COVID-19 prognostics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.13.23297016
DO 10.1101/2023.10.13.23297016
A1 Illibauer, Jennifer
A1 Clodi-Seitz, Tamara
A1 Zoufaly, Alexander
A1 Aberle, Judith H.
A1 Weninger, Wolfgang J.
A1 Foedinger, Manuela
A1 Elsayad, Kareem
YR 2023
UL http://medrxiv.org/content/early/2023/10/15/2023.10.13.23297016.abstract
AB Blood Plasma Viscosity (PV) is an established biomarker for numerous diseases. While PV colloquially refers to the shear viscosity, there is a second viscosity component--the bulk viscosity--that describes the irreversible fluid compressibility on short time scales. The bulk viscosity is acutely sensitive to solid-like suspensions, and obtainable via the longitudinal viscosity from acoustic attenuation measurements. Whether it has diagnostic value remains unexplored yet may be pertinent given the association of diverse pathologies with the formation of plasma suspensions, such as fibrin-microstructures in COVID-19 and long-COVID. Here we show that the longitudinal PV measured using Brillouin Light Scattering (BLS) can serve as a proxy for the shear PV of blood plasma, and exhibits a temperature dependence consistent with increased suspension concentrations in severe COVID-patient plasma. Our results open a new avenue for PV diagnostics based on the longitudinal PV, and show that BLS can provide a means for its clinical implementation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the Austrian Science Fund-FWF (Grant No. P34783).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Austrian Federal Agency for Safety in Health Care (BASG) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData for this study are available in the Main Text or Supplementary Materials, and where not the case, will be made available upon publication via a DOI repository such as Zenodo.